Fetal hydantoin syndrome (FHS) is a complex of congenital anomalies caused by prenatal exposure to hydantoin and its derivatives, often used as antiepileptic drugs. The main manifestations of this syndrome are characteristic physical abnormalities, including anomalies of the hands and limbs, craniofacial deformities, and mental retardation. This pathology belongs to the group of drug-induced disorders and manifests itself as a result of the effect of ternogenic factors on the developing fetus in the first trimester of pregnancy.
History of the disease and interesting historical facts
Fetal hydantoin syndrome was first described in the 1970s, when researchers began to note a link between hydantoin use and abnormalities in newborns. The study of this syndrome was made possible by the work of a number of scientists who began systematically collecting data on the effects of antiepileptic drugs on fetal development. One of the first studies was the observation of a group of women who took hydantoin during pregnancy, which resulted in the recording of recurring patterns of abnormalities. In subsequent years, it was discovered that the syndrome could occur not only in children of mothers taking hydantoin, but also in cases where other antiepileptic drugs, such as carbamazepine and valproic acid, were used.
Epidemiology
The epidemiology of fetal hydantoin syndrome varies by region and population. According to various studies, the incidence of FHS among children whose mothers took hydantoin during pregnancy ranges from 2% to 5%. At the same time, in groups of mothers taking several antiepileptic drugs at the same time, the risk of developing the syndrome increases significantly. It is important to note that the level of FHS diagnosis may affect statistics, since not all cases are detected and registered.
Genetic predisposition to this disease
Genetic predisposition to fetal hydantoin syndrome is associated with polymorphisms in several genes involved in drug metabolism and elimination. The main genes involved include CYP2C9 and CYP2C19, which are responsible for hydantoin metabolism. Alterations in these genes may result in decreased ability to metabolize the drug, which in turn increases the risk of its toxic effects on the developing fetus. Research also points to the possibility of geno-oxidative stress as an additional mechanism contributing to the development of anomalies.
Risk factors for the development of this disease
Risk factors for fetal hydantoin syndrome include:
- Taking antiepileptic drugs, especially hydantoin.
- Inadequacy of drug dosage depending on the mother's body weight.
- Concomitant medical conditions, including chronic diseases that require long-term therapy with similar agents.
- Long-term use of drugs that alter the metabolism of hydantoin in the body.
Diagnosis of this disease
Diagnosis of fetal hydantoin syndrome includes several stages and methods:
- Main symptoms: the presence of characteristic anatomical anomalies, changes in the craniofacial region, and disturbances in the formation of the limbs.
- Laboratory tests: analysis of the mother's medical history, blood hydantoin level.
- Radiological examinations: Ultrasound to assess fetal developmental abnormalities.
- Other types of diagnostics: comprehensive assessment of the physical and neuropsychological development of the child after birth.
- Differential diagnosis: exclusion of other fetal syndromes and genetic diseases.
Treatment
Treatment of fetal hydantoin syndrome is a multifaceted process that includes:
- General treatment: adjustment of the action of antiepileptic drugs, if possible, during pregnancy.
- Pharmacological treatment: the use of medications to correct symptoms, such as anticonvulsants and nootropics.
- Surgical treatment: In the presence of severe anatomical abnormalities, surgical intervention may be required.
- Other types of treatment: rehabilitation and psychotherapeutic approaches to support child development.
List of medications used to treat this disease
The main groups of drugs used in the treatment of complications of fetal hydantoin syndrome include:
- Anticonvulsants: valproic acid, carbamazepine.
- Nootropics: piracetam, cerebrolysin.
- Medicines for the correction of endocrine disorders (if any).
Disease monitoring
Monitoring of fetal hydantoin syndrome includes regular assessment of the child's physical and mental state, which allows for timely detection of possible complications. The main control stages are:
- Regular visits to a pediatrician and neurologist.
- Assessment of motor and cognitive activity.
- The predicted outcome depends on the severity of the syndrome, but with early rehabilitation many children achieve satisfactory results.
- Complications may include developmental delay, mental impairment, and secondary disability.
Age-related features of the disease
Fetal hydantoin syndrome may present differently depending on the age group:
- In newborns: severe physical abnormalities observed immediately after birth.
- In young children: difficulties in psychomotor development, delayed speech development.
- In adolescents: consequences of psychological and social adaptation to many difficulties in life.
Questions and Answers
- What is fetal hydantoin syndrome? This is a complex of congenital anomalies that arise due to the effect of hydantoin on the developing fetus.
- What are the main symptoms of the disease? Characteristic features include limb malformations, craniofacial deformities, and mental retardation.
- What factors increase the risk of developing the disease? Important factors include the use of hydantoin during pregnancy and the presence of concomitant diseases in the mother.
- How is fetal hydantoin syndrome diagnosed? Diagnosis is made through symptom assessment, laboratory and radiological examinations.
- What is the prognosis for this syndrome? The prognosis depends on the severity of the anomalies and the timeliness of intervention; many children with early rehabilitation achieve good results.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends the following when working with patients at risk for fetal hydantoin syndrome:
- Advise women planning pregnancy to discuss possible risks with their doctor and, if necessary, reconsider antiepileptic therapy.
- Recommend fetal monitoring with ultrasound and genetic testing if risk is high.
- Refer for psychological and pedagogical testing and rehabilitation after birth to assess and support the child's development.
